Clinical Trials in San Diego

Showing 181-200 of 7,028 trials

ACTIVE_NOT_RECRUITINGPHASE2/PHASE3< 1 mile

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

Netherton Syndrome

Quoin Pharmaceuticals30 participantsStarted Jun 2022

San Diego, California, United States • Indianapolis, Indiana, United States • Quincy, Massachusetts, United States +2 more locations

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

Primary Prevention of Atherosclerotic Cardiovascular Disease

Novartis Pharmaceuticals14,078 participantsStarted Mar 2023

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Fairhope, Alabama, United States +984 more locations

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Find Trials by Condition in San Diego

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

An International Observational Study of Adults With Acute Infection

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)